Docetaxel polymeric micelle - Samyang

Drug Profile

Docetaxel polymeric micelle - Samyang

Alternative Names: B 5704; Docetaxel-PM; NanoxelM; SYP-0704A

Latest Information Update: 14 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Samyang Biopharmaceuticals Corporation; Samyang Group
  • Developer Samyang Biopharmaceuticals Corporation
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Head and neck cancer
  • Phase III Bladder cancer

Most Recent Events

  • 31 Dec 2016 Phase-III clinical trials in Bladder cancer (Second-line therapy or greater, Treatment-experienced) in South Korea (Intravesicular) (NCT02982395)
  • 20 Jul 2016 Launched for Head and neck cancer in South Korea (Parenteral) before July 2016
  • 01 Oct 2015 Phase-II clinical trials in Head and neck cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in South Korea (IV) (NCT02639858)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top